Pomerantz Law Firm Probes Allegations of Securities Fraud at Lantheus Holdings

Investor Alert: Pomerantz Law Firm Investigates Lantheus Holdings

Pomerantz LLP has embarked on an investigation regarding claims made on behalf of investors of Lantheus Holdings, Inc. (NASDAQ: LNTH). The primary focus of this inquiry is to determine whether Lantheus, alongside some of its executives and board members, has been involved in any form of securities fraud or engaged in unethical business practices, which could impact shareholder interests.

The investigation follows a concerning announcement made by Lantheus on August 6, 2025. During this announcement, the company disclosed disappointing financial results for the second quarter of 2025. Shareholders learned that the earnings-per-share (EPS) and revenue figures fell short of market expectations. Furthermore, the company revised its revenue forecast for the full year of 2025, from an anticipated range of $1.55 to $1.585 billion, down to a new estimate between $1.475 and $1.51 billion. Additionally, the projected adjusted fully diluted EPS guidance was also decreased from $6.60 - $6.70 per share to $5.50 - $5.70 per share.

During the earnings call that coincided with the announcement, Lantheus's Chief Executive Officer underscored the mounting pricing pressures within the PSMA PET market. He implied that, as part of a strategy to protect the long-term value of their franchise, the company decided to forgo certain volumes from specific accounts. Adding to the grim picture painted by executives, the Chief Financial Officer remarked that consolidated net revenue for the second quarter amounted to $378 million, representing a decline of 4.1%. Most notably, the radiopharmaceutical product PYLARIFY, considered a vital asset for Lantheus in oncology, generated sales of $250.6 million, a stark decrease of 8.3%, which was also below prior expectations.

The fallout from this news was substantial; Lantheus's stock plummeted by $20.76 per share on August 6, a staggering drop of 28.58%, closing the day at $51.87. This dramatic shift in stock value raised significant concerns among investors, given the compounding factors of lowered forecasts and potential mismanagement.

Pomerantz LLP, well-regarded for its expertise in corporate and securities litigation, has built a reputation over its 85 years of service as a leading firm in class action lawsuits. The firm, founded by the late Abraham L. Pomerantz, has historically championed the rights of individuals facing securities fraud and breaches of fiduciary duty, recovering millions in damages on numerous occasions. Investors believing they have been adversely affected by Lantheus's actions are encouraged to reach out to Danielle Peyton at Pomerantz for further assistance and to possibly join the class action lawsuit against the company.

To contact, you can reach Danielle Peyton at [email protected] or call 646-581-9980, ext. 7980.

For those impacted or who wish to learn more about Pomerantz’s investigation, further details can be found on their official website here. Investors are reminded that attorney advertising exists, and prior results do not guarantee similar outcomes in the future.

Thus, as Lantheus navigates through this challenging scenario, it’s crucial for shareholders to stay informed and take necessary actions to protect their interests as the situation evolves.